Drug Trial Radar · NCT05537025
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jan 30, 2023
Primary completion
Sep 5, 2025
Study completion Sep 5, 2025
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF). The study will initiate with NHVs receiving single ascending doses of ARO-MMP7. Following evaluation of safety and pharmacodynamic (PD) data, participants will receive multiple doses of ARO-MMP7.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
ARO-MMP7 Inhalation SolutionDrug
ARO-MMP7 by inhalation of nebulized solution
PlaceboDrug
Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 up to Day 85
Locations
19 sites in 6 countries. Site status is shown where the registry gives one.
Research Site 1
Copenhagen, Denmark
Research Site 2
Odense, Denmark
Research Site 1
Ancona, Italy
Research Site 2
Florence, Italy
Research Site 3
Milan, Italy
Research Site 4
Milan, Italy
Research Site 5
Milan, Italy
Research Site 1
Auckland, New Zealand
Research Site 2
Christchurch, New Zealand
Research Site 2
Seoul, South Korea
Research Site 3
Soeul, South Korea
Research Site 1
Ulsan, South Korea
Research Site 1
Barcelona, Spain
Research Site 2
Oviedo, Spain
Research Site 3
Santander, Cantabria, Spain
Research Site 1
Birmingham, United Kingdom
Research Site 2
Edinburgh, United Kingdom
Research Site 4
Manchester, United Kingdom
Research Site 3
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.